Brokerages Set Karyopharm Therapeutics Inc (KPTI) Price Target at $14.39

Karyopharm Therapeutics Inc (NASDAQ:KPTI) has been given an average recommendation of “Buy” by the eleven brokerages that are currently covering the company. One equities research analyst has rated the stock with a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $14.76.

Several analysts have commented on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 price objective on shares of Karyopharm Therapeutics in a report on Monday, May 15th. Jefferies Group LLC restated a “buy” rating and issued a $17.00 target price on shares of Karyopharm Therapeutics in a research report on Friday, April 7th. Robert W. Baird restated an “outperform” rating and issued a $15.00 target price on shares of Karyopharm Therapeutics in a research report on Thursday, April 6th. Wedbush restated an “outperform” rating and issued a $14.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, April 5th. Finally, Zacks Investment Research upgraded Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 21st.

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) traded up 1.53% on Monday, reaching $9.95. 173,554 shares of the company’s stock were exchanged. The firm’s market cap is $468.82 million. The company has a 50 day moving average price of $10.53 and a 200 day moving average price of $10.16. Karyopharm Therapeutics has a one year low of $6.27 and a one year high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Thursday, May 4th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.67) by $0.04. The business had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.02 million. During the same quarter in the prior year, the firm posted ($0.75) earnings per share. Analysts expect that Karyopharm Therapeutics will post ($2.68) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Brokerages Set Karyopharm Therapeutics Inc (KPTI) Price Target at $14.39” was first published by sleekmoney and is the property of of sleekmoney. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://sleekmoney.com/brokerages-set-karyopharm-therapeutics-inc-kpti-price-target-at-14-39/1839356.html.

Institutional investors have recently added to or reduced their stakes in the stock. Teza Capital Management LLC purchased a new position in Karyopharm Therapeutics during the first quarter valued at $169,000. American International Group Inc. increased its position in Karyopharm Therapeutics by 20.9% in the first quarter. American International Group Inc. now owns 16,422 shares of the company’s stock valued at $211,000 after buying an additional 2,836 shares during the period. C WorldWide Group Holding A S increased its position in Karyopharm Therapeutics by 30.2% in the first quarter. C WorldWide Group Holding A S now owns 16,928 shares of the company’s stock valued at $217,000 after buying an additional 3,928 shares during the period. Metropolitan Life Insurance Co. NY increased its position in shares of Karyopharm Therapeutics by 12.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 21,911 shares of the company’s stock worth $206,000 after buying an additional 2,460 shares during the last quarter. Finally, Parametric Portfolio Associates LLC increased its position in shares of Karyopharm Therapeutics by 38.6% in the first quarter. Parametric Portfolio Associates LLC now owns 27,988 shares of the company’s stock worth $359,000 after buying an additional 7,789 shares during the last quarter. Institutional investors and hedge funds own 56.97% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

12 Month Chart for NASDAQ:KPTI

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/brokerages-set-karyopharm-therapeutics-inc-kpti-price-target-at-14-39/1839356.html

Receive News & Ratings for Karyopharm Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *